Skip to content

Virtual Reality in Aphasia Telerehabilitation

Combining Immersive Virtual Reality With Telerehabilitation to Provide Language Intervention for People With Aphasia: A Randomized Waitlist Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04828759
Enrollment
20
Registered
2021-04-02
Start date
2021-04-01
Completion date
2025-12-31
Last updated
2021-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aphasia, Acquired

Keywords

aphasia, virtual reality, head-mounted device, rehabilitation, telerehabilitation

Brief summary

The main purpose of this study is to evaluate the use of the immersive 3D HMD VR technology in the language intervention with a home-based telerehabilitation approach for people with aphasia. The assessments will be conducted at the baseline (prior the intervention periods) and after each intervention period (i.e. after the VR-intervention period and the waitlist period).

Detailed description

The purpose of the present project is to study the effects, feasibility, and the participants' experiences of this novel kind of language intervention. The effects of the intervention will be studied with various outcome measures in terms of language performance, functional communication, and quality of life. The aim is to explore the VR-intervention on the group level and with a randomized waitlist control group design (or delayed crossover design). In this study, the people with aphasia will be practicing at their home with support of their relatives, and participants will also receive regular remote guidance by a speech and language therapist (SLT) during the intervention. The relatives are also involved in the assessment process.

Interventions

BEHAVIORALVR-treatment

The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places

BEHAVIORALTreatment as usual

The participants will be randomized either to group which receives the VR-intervention immediately (A) or to the waitlist control group (B). After the baseline assessment, the participants in the group A participate VR-intervention lasting for 8 weeks, and the participants in the group B will receive 8 weeks waitlist period. After the 8 weeks, the groups switch their places

Sponsors

Peili Vision Oy
CollaboratorUNKNOWN
Verve Oulu
CollaboratorUNKNOWN
City of Oulu
CollaboratorUNKNOWN
University of Oulu
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Post-stroke aphasia ≥ 3 months from stroke * Age 18-75 years * Finnish as a native language * Relative have the motivation and willingness to support person with aphasia in rehabilitation process * At least some level of spoken output * Moderate-to-severe aphasia * Deficit in a word retrieval process

Exclusion criteria

* Participation in other intervention study during the study * Participation in other traditional speech and language therapy during the VR-intervention (i.e. 9-10 weeks period). * Severe and current psychotic disorder * Dementia/other neurodegenerative disease * History of previous stroke (/strokes) if not recovered, excluding TIAs (the criteria for the recovery: no residual aphasia or other disabilities caused by stroke which would affect in significant manner on everyday life) * Active epilepsy / migraine (\< 3 years) * Severe apraxia of speech * Inability to act according to given instruction * Severe neuropsychological disorder or the decline of cognitive / memory functions, which would significantly affect for training during the VR-intervention * Vision or hearing impairment which would prevent the use of VR HMD * if the participant's treatment or medication is unsuitable with the use of VR HMD device as assessed by the physician * if the participant has the pacemaker or implantable (electric) medical device

Design outcomes

Primary

MeasureTime frameDescription
Change in quality of life from baseline to week 9 and to week 18Change from baseline to week 8 and to week 18Quality of life is assessed with Stroke and Aphasia Quality of Life Scale-39 (SAQOL-39), performed at the baseline (prior the intervention periods) and after each intervention period (i.e. after the VR-intervention period and the waitlist period)
Change in language abilities from baseline to week 9 and to week 18Change from baseline to week 9 and to week 18Language abilities are assessed using language quotient LQ score of Western Aphasia Battery (WAB), performed at the baseline (prior the intervention periods) and after each intervention period (i.e. after the VR-intervention period and the waitlist period)
Change in naming abilities from baseline to week 9 and to week 18Change from baseline to week 9 and to week 18Naming abilities for nouns and verbs are assessed with Boston Naming Test (BNT) and TNT-test (action naming test in Finnish) performed at the baseline (prior the intervention periods) and after each intervention period (i.e. after the VR-intervention period and the waitlist period)
Change in verbal fluency from baseline to week 9 and to week 18Change from baseline to week 9 and to week 18Verbal fluency is assessed using multiple categories (produced words per one minute in each category), performed at the baseline (prior the intervention periods) and after each intervention period (i.e. after the VR-intervention period and the waitlist period)
Change in functional communication skills from baseline to week 9 and to week 18Change from baseline to week 9 and to week 18Functional communication skills are assessed with Communication Effectiveness Index (CETI), performed at the baseline (prior the intervention periods) and after each intervention period (i.e. after the VR-intervention period and the waitlist period)

Secondary

MeasureTime frameDescription
Attrition rates during the study.Through study completion, up to 18 weeksAmount of drop outs of participants during the study,
Participants' experiences of the VR-interventionAfter VR-intervention period, at the week 9 or at the week 18, depending of the group the patient has been randomizedThe structural survey of participants' experiences of the VR-intervention.
Data collected by VR-devices regarding the performance of participants during the VR-interventionThrough the VR-intervention up to 8 weeks or through the weeks 10-17, depending of the group the patient has been randomizedAmounts of training (in minutes) and e.g. naming speed and range of head movements collected automatically by VR-devices
Date collected by remote sessions regarding the experiences of participants and feasibility of VR-interventionWeekly during the VR-intervention up to 8 weeks or through the weeks 10-17, depending of the group the patient has been randomizedData collected with semi-structural interview during remote guidance sessions (8 times during the VR-period) by the researcher. In addition, participants will be able to contact the researcher freely during the 8 weeks VR-intervention period.
Participants' experiences of the waitlist periodAfter waitlist period, at the week 9 or at the week 18, depending of the group the patient has been randomizedThe structural survey of participants' experiences of the waitlist period

Contacts

Primary ContactMatti Lehtihalmes, Professor
matti.lehtihalmes@oulu.fi+358407024320
Backup ContactEmilia Malinen, MA
emilia.malinen@oulu.fi+358407194250

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026